Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.9B | $21.9B | $18.3B | $16.9B | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Revenue growth | — | -0.2% | -16.4% | -7.6% | -1.4% | -4.7% | -6.0% | 6.2% | 4.4% | 4.3% |
| Gross profit | $11.7B | $10.6B | $8.30B | $7.54B | $7.73B | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| Gross margin | 53.2% | 48.6% | 45.4% | 44.6% | 46.4% | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| Operating income | $2.15B | -$17.5B | -$1.64B | -$443M | -$3.57B | $1.72B | -$2.20B | $433M | -$303M | $2.16B |
| Operating margin | 9.8% | -80.0% | -9.0% | -2.6% | -21.4% | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Net income | $329M | -$16.3B | -$2.15B | -$999M | -$3.99B | $417M | -$2.45B | -$559M | -$1.64B | $1.41B |
| Net margin | 1.5% | -74.4% | -11.8% | -5.9% | -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
| EPS (diluted) | $0.07 | -$16.26 | -$2.35 | -$0.91 | -$3.64 | $0.38 | -$2.20 | -$0.50 | -$1.45 | $1.21 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.89B | $2.23B | $2.45B | $748M | $1.22B | $798M | $1.59B | $1.37B | $1.25B | $1.65B |
| Capital expenditures | $901M | $874M | $651M | $525M | $578M | $562M | $548M | $526M | $498M | $501M |
| Free cash flow | $2.99B | $1.35B | $1.79B | $223M | $638M | $236M | $1.04B | $842M | $749M | $1.15B |
| Dividends paid | $1.30B | $901M | $12.0M | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $988M | $963M | $1.78B | $1.98B | $2.18B | $2.17B | $2.80B | $3.23B | $3.30B | $3.56B |
| Total assets | $93.1B | $70.6B | $60.7B | $57.5B | $50.6B | $47.7B | $45.9B | $43.5B | $39.3B | $40.7B |
| Total liabilities | $58.1B | $51.9B | $44.9B | $42.4B | $39.6B | $36.4B | $36.1B | $35.4B | $33.6B | $32.8B |
| Long-term debt | $32.5B | $28.8B | — | — | — | — | — | — | — | — |
| Shareholders' equity | $33.3B | $17.4B | $14.7B | $14.0B | $10.0B | $10.3B | $7.80B | $7.51B | $5.37B | $7.91B |
| Retained earnings | $13.6B | -$3.80B | -$5.96B | -$6.96B | -$10.9B | -$10.5B | -$11.7B | -$13.5B | -$15.2B | -$13.8B |
| Shares (wtd avg diluted) | 961M | 1.02B | 1.02B | 1.09B | 1.09B | 1.11B | 1.11B | 1.12B | 1.13B | 1.16B |
Every figure is extracted from TEVA PHARMACEUTICAL INDUSTRIES LTD’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.